Baricitinib ameliorates behavioral deficits and NLRP3-related neuroinflammation in a ketamine rat model of schizophrenia: Role of JAK2/STAT3 and PI3K/AKT/mTOR signaling.
International immunopharmacology · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
AnimalsPurinesSulfonamidesJanus Kinase 2TOR Serine-Threonine KinasesMaleSchizophreniaSTAT3 Transcription FactorSignal TransductionProto-Oncogene Proteins c-aktDisease Models, AnimalPhosphatidylinositol 3-KinasesKetamineRatsPyrazolesAzetidinesNLR Family, Pyrin Domain-Containing 3 ProteinNeuroinflammatory DiseasesRats, Sprague-DawleyNeuroprotective AgentsBehavior, AnimalHumansCytokinesBaricitinibJAK2/STAT3NeuroinflammationPI3K/AKT/mTOR
Come citare questo studio
Ali A Albariqi, Dalia A Nawwar, Weam W Ibrahim, Mahmoud M Khattab. (2026). Baricitinib ameliorates behavioral deficits and NLRP3-related neuroinflammation in a ketamine rat model of schizophrenia: Role of JAK2/STAT3 and PI3K/AKT/mTOR signaling.. International immunopharmacology. DOI: 10.1016/j.intimp.2026.117303
Consulta la pubblicazione originale ↗